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Abstract
Acute rhinosinusitis (ARS) is a sudden, symptomatic inflammation of the nasal and paranasal
mucosa. It is usually caused by respiratory virus infection, but bacteria complicate for a small
number of ARS patients. The differential diagnostics between viral and bacterial pathogens is
difficult and currently no rapid methodology exists, so antibiotics are overprescribed. The electronic
nose (eNose) has shown the ability to detect diseases from gas mixtures. Differential mobility
spectrometry (DMS) is a next-generation device that can separate ions based on their different
mobility in high and low electric fields. Five common rhinosinusitis bacteria (S. pneumoniae, H.
influenzae, M. catarrhalis, S. aureus, and P. aeruginosa) were analysed in vitro with DMS.
Classification was done using linear discriminant analysis (LDA) and k-nearest neighbour (KNN).
The results were validated using leave-one-out cross-validation and separate train and test sets.
With the latter, 77% of the bacteria were classified correctly with LDA. The comparative figure
with KNN was 79%. In one train-test set, P. aeruginosa was excluded and the four most common
acute rhinosinusitis bacteria were analysed with LDA and KNN; the correct classification rate was
83% and 85%, respectively. DMS has shown its potential in detecting rhinosinusitis bacteria in
vitro. The applicability of DMS needs to be studied with rhinosinusitis patients.
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Introduction
Acute rhinosinusitis (ARS) is a sudden, symptomatic inflammation of the nasal and paranasal
mucosa. It is usually caused by respiratory virus infection, but bacterial prevalence remains poorly
defined. In two often-cited studies [1, 2], the bacterial prevalence was 0.5–2%, but according to a
recent meta-analysis [3], the prevalence is likely higher. Autio et al. (2015) have found bacterial
causes in 40% of cases [4]. In Finland (2016), 1.3% of all patient visits to daily outpatient practices
are due to ARS [5]. In a study conducted in Asia, it was estimated that 6–10% of appointments with
a doctor are due to ARS [6].
Antibiotics are usually prescribed, even though their effect is limited in clinically diagnosed,
uncomplicated ARS [7]. The most common bacteria in ARS are Streptococcus pneumoniae,
Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus [8]. One explanation for
the poor antibiotic response is that only 40% of ARS are bacterial culture-positive [4]. Nasal
endoscopy provides the possibility to take microbiological samples from the middle meatus, but
equipment is only available to ear, nose, and throat (ENT) specialists. A maxillary sinus puncture and
aspiration can be considered the gold standard in diagnosing bacterial ARS, but it seems that
endoscopically directed middle meatal cultures correlate well with aspiration [9].
Since the early days of medicine, doctors have linked certain diseases to specific smells. During the
last decades dogs’ ability to detect certain diseases by smelling have been studied [10]. Dogs use in
clinical practice has pitfalls due to extensive training and their limited life-span. The odour emitted
from our bodies consists of volatile organic compounds (VOCs) [11–13]. Endogenous VOCs are
released as by-products of normal cell metabolism, but also directly by microbes or due to an
inflammatory response to infection [11]. Certain VOCs can be specific biomarkers of diseases [13].
Most commonly, however, patterns of multiple VOCs perform better than isolated biomarkers [14].
The electronic nose (eNose) is a device that attempts to mimic mammalian olfactory sense. It
comprises an array of nonselective chemical sensors, pre-processing electronics, and a computer that
interprets sensor signals [15]. Different kinds of sensor arrays exist – for example, metal–oxide–
semiconducting field-effect transistors (MOSFET), conducting polymer sensors, and optical sensors
[15]. The eNose can also be constructed with more than one type of sensor. VOCs interact with
sensors and produce a so-called smell print. The chemical characteristics of VOCs determine the
response pattern of the eNose, which can be measured. The eNose does not differentiate specific
components of the smell print [16], and it therefore performs a qualitative rather than a quantitative
analysis.
Differential mobility spectrometry (DMS), although not an eNose in the strictest sense, provides
analogous information from gas mixtures. The DMS is highly more sensitive and selective device
compared to the classic eNose. Devices with voltage adjustable ion filters have an enhanced ability
to analyse complex samples without precipitation. The principle of DMS is explained thoroughly in
other publications [17, 18]. Analogously to commonly used electrophoresis, the device separates the
molecular mixture to its components, creating a data matrix also known as a dispersion plot or a
“chemical fingerprint” of the sample. The dispersion plot is usually represented as a heat map color-
scheme. The working principle of the method is illustrated in Figure 1.
Several studies have shown the ability of the eNose to detect diseases from gaseous headspace – for
example, differentiating prostatic cancer from benign prostatic hyperplasia [19] or diagnosing head
and neck cancer [20], tuberculosis [21], and ventilator acquired pneumonia [22]. In a study by Thaler
and Hanson (2006), the eNose was able to diagnose acute bacterial rhinosinusitis with a 72%
probability [23].
There is a need for a new, easy-to-use tool for diagnosing rhinosinusitis bacteria, and the eNose has
strong potential in this application. In addition, DMS provides next-generation technology to the
eNose field. Our aim was to study whether DMS could identify common acute (S. pneumoniae, H.
influenzae, M. catarrhalis) and chronic (S. aureus, P. aeruginosa) rhinosinusitis bacteria in vitro.
Materials and methods
FIMLAB (Tampere, Finland) laboratories provided the cultures of all five bacteria species. The
bacteria were identified using standard biochemical methods and matrix-assisted laser
desorption/ionisation time-of-flight (VITEK® MS, bioMérieux, Marcy-l’Étoile, France). Since H.
influenzae grows only on chocolate agar, it was used as the growth medium for all the bacterial species
to avoid a confounding effect from the medium.
The device, Figure 2, used in this study was an Envi-AMC (Environics Ltd, Mikkeli, Finland). It is
based on DMS technology, utilising Americium 241Am as an ionisation source. Dried and activated
charcoal- and molecular sieve (5Å)-filtered compressed air was used as a carrier gas. The device was
connected to a cloud database (Olfactomics Ltd, Tampere, Finland) for the monitoring and logging
of the data. Two individual devices were used in the study due to the sensor malfunction of the first
device.
The measurement sessions were initiated with a baseline measurement with tap water. Each bacterial
plate was measured twice, producing two measurements per sample. The device must be rinsed with
water after every culture plate to control for carry-over. Based on our previous studies with the device,
two water measurements are usually enough for rinsing. Each measurement produces a dispersion
plot which is presented in the graphical user interface of the device. The dispersion plot was visually
assessed for contamination. If significant contamination was noted, water measurements were
repeated to rinse the system with water vapours until the dispersion plot had returned to baseline. The
measurement cycle with two water measurements takes approximately 15 minutes. The bacteria were
measured in random order with each bacteria spread over multiple sessions in order to avoid bias
from sensor drift.
The analysis was made with Matlab (The MathWorks, Natick, MA, USA). Linear discriminant
analysis (LDA) and k-nearest neighbour (KNN) methods were used to classify samples. To avoid
overfitting, the results were cross-validated by using leave-one-out cross-validation (LOOCV) and
separate train and test sets. In LOOCV, each sample was removed from the sample set and then
classified with the data of the remaining samples. When using train and test sets, a randomly selected
30% of the samples (test set) was removed from the sample set and then classified with the data of
the remaining 70% (train set). This was repeated five times because of the randomisation element,
and the mean classification rate of the five drives was used in the final results.
A total of 107 samples were analysed. Of these samples, there were 24 samples of S. aureus, 22
samples of P. aeruginosa, 26 samples of S. pneumoniae, 21 samples of H. influenzae, and 14 samples
of M. catarrhalis. A total of 222 individual measurements were made (49 of S. aureus, 45 of P.
aeruginosa, 52 of S. pneumoniae, 46 of H. influenzae, and 30 of M. catarrhalis). One sample of S.
aureus was measured only once and two samples were measured three times. One sample of P.
aeruginosa was measured three times. Two samples of H. influenzae were measured four times, as
was one sample of M. catarrhalis.
Results
Using LOOCV, 77% of the bacteria were classified correctly with LDA. With KNN, when k=1, the
classifications were 84% correct. When k was 2 and 3, the correct classification was 93% and 76%,
respectively.
Using separate train and test sets, the mean correct classification rate with LDA was 77%. With KNN,
when k=1, the classification rate was 79.0%.
We also wanted to see how well the eNose discriminates only the ARS bacteria, so P. aeruginosa
samples were excluded from the data. In this scenario, with LOOCV, LDA classified 84% of the
samples correctly, while KNN, when k=1, classified 92% of the samples correctly. With the train and
test sets, LDA had a mean classification rate of 83%, and with KNN, when k=1, the classification
rate was 85%.
The performance of the KNN classifiers are presented as a so-called confusion matrix in Tables 1
and 2. Examples of the dispersion plots of the bacterial samples are shown in Figure 3.
Discussion
Our results show that DMS is able to discriminate five different rhinosinusitis bacteria and the four
most common ARS bacteria with a reasonably high accuracy. Since the microbiological cause of
ARS is challenging and time-consuming to diagnose, these results lay the foundations for a new
diagnostic approach.
To our knowledge, there are few in vitro studies concerning the eNose and ENT bacteria [24, 25]. Lai
et al. (2002) used Cyranose 320 (Cyrano Technologies, Pasadena, CA, USA) in their in vitro analysis
of ten common upper respiratory bacteria, which included those tested in our study, but also others,
such as Streptococcus Group A, Klebsiella species, and Proteus mirabilis. The eNose was able to
distinguish three tested bacteria from control swabs. Lai et al. also tested discrimination ability across
a variety of bacterial species, but in quite many cases, the eNose gave false results. Moreover,
cross-validation was not used, giving overoptimistic results for the performance of the eNose [24].
Thaler et al. (2008) examined the ability of the Cyranose 320 to distinguish biofilm-producing
Pseudomonas and Staphylococcus from non-biofilm-producing strains of the same species [25]. The
samples were tested over 24 days along with control data saline to check the consistency of the sensor
responses. Consistent responses were received for 22 days. Internal validation was performed using
the leave-one-day-out method. Furthermore, they also divided the data into training and testing sets
with success rates ranging from 72% to 100%, which are quite similar to ours. Although Thaler et
al.’s sample size was larger (198 samples of each bacteria), our study tested five different bacteria
species. The technology in Cyranose 320 relies on conducting-polymer sensors, which have lower
sensitivity, specificity, and accuracy than DMS [26]. In addition, the conducting-polymer sensors
suffer from irreversible contamination.
Our analysis also used bacteria in vitro. There are a few limitations regarding the study method. First,
we acquired bacterial plates from a laboratory, and there was variance in the duration of plate storage
in the refrigerator before measurements. Some were measured on the same day and some after a few
days. Analysing all species over multiple sessions minimised bias from this variation. It is not known
if some or all of the bacteria on the plate had died before measurement. This could lead to a weaker
smell print but, on the other hand, it is also possible that bacteriolysis releases molecules that actually
enhance detection. In addition, there was unavoidable variance in the confluence of the bacteria on
the agar plate, which could affect DMS performance. As seen from the confusion matrix presented in
Table 1, the device distinguishes all S. aureus correctly, but there are false estimates between P.
aerigunosa and M. catarrhalis and also between H. influenzae and S. pneumoniae, demonstrating that
there are probably similarities in the gaseous headspace of these bacteria. We must also emphasise
that the specific molecules detected by the eNose are unknown. Thus, the smell print might change
when the sample is acquired from a patient because there are also other molecules affecting it, such
as those produced by the host inflammatory response. Two preliminary clinical trials have been
conducted concerning rhinosinusitis diagnostics with the eNose [23, 27]. Nasal out-breath was
sampled in both studies. The correct results varied between 60% and 72% with a modest sample size
and limited cross-validation.
There are many types of eNose sensor, and they all have their strengths and weaknesses. For
example, surface acoustic wave sensors benefit from their high sensitivity to a broad spectrum of
VOCs and relatively low costs in biomedical applications, but they suffer from reproducibility
issues [14]. Metal oxide-semiconductor sensors, on the other hand, are easier to reproduce but
suffer from poor long-term stability.
The eNose in this study is based on DMS technology [17], which has been studied in various medical
applications [18], but to our knowledge there are no publications regarding bacteria affecting the ENT
area. The advantages of DMS include its high sensitivity and its ability to work at room temperature.
Device-to-device variation is also limited, as we demonstrated in our study by changing the sensor
during the study period. Its disadvantage is its susceptibility to contamination, which requires the
sensors to be rinsed with water vapours between measurements.
The eNose produces multidimensional data, which requires pre-processing and classification to build
a model. A variety of techniques for data analysis exists, but there is no consensus as to which one is
best [28]. Therefore, depending on the sensor and application, different methods should be tested. A
recent review [28] aimed to give an overview of the currently used dimension reduction,
classification, and validation methods. Although cross-validation is considered crucial [19], a
literature review regarding the investigation of exhaled breath and eNoses yielded 46 studies, with
internal validation performed in 29 (63%) studies and external validation performed only in 7 (15%)
studies. In our study, the optimal data analysis method gave correct results in 93% of cases. To
minimise the risk of overfitting, we utilised the leave-one-out method for internal validation in all
measurements. External validation with the train-test set, which is considered the most robust method
of cross-validation [29], yielded a correct classification rate of 79%, which is still an excellent result
considering the modest sample size. We therefore consider our methods of cross-validation adequate.
At the moment, Gram staining and a bacterial culture are the gold standard for microbial identification
from samples. They are cheap and easy to do but requires laboratory setting and staff.  For all the
bacteria tested in our study, it usually takes one day to get the results in culture and approximately a
day more for information about antibiotic sensitivity.
DMS can analyse complex samples in real-time without prior sample preparation. For example, it can
differentiate Clostridium difficile- positive stool samples from negative ones with high accuracy [30].
DMS has also shown ability to differentiate methicillin-resistant S. aureus from methicillin-sensitive
S. aureus [31]. Its high sensitivity allows detection of compounds even in low concentration. Our
device is easy to use and the actual measurements can be done by almost anyone after brief
instructions.
Although in this study we analysed bacterial plates, the same methodology can be applied to a clinical
setting. Samples acquired from rhinosinusitis patients can be analysed with DMS easily. An empty
agar plate can be covered with pus collected from the maxillary sinus or middle meatus and analysed
in the same manner as we did with the bacterial plates. The results can be compared with the results
presented in this study. Our device does not have data-processing software within itself. Therefore, it
does not give an instant result which bacteria grows in a sample. Thus, it is not yet possible to use the
device in a clinical practice. Technically, there is only need for an analysis software to be integrated
to the device to have an instant result after measurement. The device has a clear potential for point-
of-care use since it is relatively compact in size, works in room temperature, utilizes ambient air as
carrier gas and tap water for rinsing. Since DMS analyses bacterial headspace, it is also relatively
easy to develop an analytical method for the analysis of exhaled nasal air, utilising, for example,
existing methods for nasal nitric oxide measurement, analogous to the sampling used in exhaled
breath studies [32].
Conclusion
The diagnostics of bacterial ARS are uncertain, so there is a need for a new diagnostic tool. DMS has
proven its potential in detecting rhinosinusitis bacteria in vitro. The positive results remained after
rigorous cross-validation, indicating that the performance of DMS is realistic. Therefore, the device
is most likely able to distinguish between unknown samples. More studies are needed on the clinical
applications of DMS in rhinosinusitis patients.
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Legend to the Figure:
Figure 1. The working principle of DMS. DMS is analogous to electrophoresis (A) in which
molecules are driven through the medium by an electrical current. The molecules in the medium cause
drag that depends on the size and shape of the molecule. The electrical charge and mass also affect
the speed of the molecule. Due to these factors, different molecules travel at different speeds. In DMS
(B) molecules that evaporate from the sample are driven with a flow of air. They are given an electric
charge by ionization, allowing discrimination of molecules according to their charge. The molecules
then enter separation phase where they are exposed to intermittent high- and low electric fields.
Ionized molecules move towards the oppositely charged plate at different speed in low and high
fields, thus resulting in another dimension for separation. Analogously to electrophoresis, the
collisions with medium also discriminate the molecules according to their size and shape. After
separation, molecules collide with the detector, resulting in a signal.
Figure 2. Illustration of the DMS device. The bacterial plates were placed into the measurement
chamber (no 1) from which the evaporated molecules were channelled to the analyzer (no 2).
Figure 3. Examples of dispersion plots for positive ion spectrums.
Table 1. Confusion matrix of all the bacterial samples using KNN, when k=1. The rows represent
true bacterial samples and the columns represent the class in which the sample was classified. For
example, there were 46 samples of H. influenzae; 43 of them were classified correctly and 3 of them













S. aureus 49 0 0 0 0
P. aeruginosa 1 33 0 1 10
S. pneumoniae 2 0 43 5 2
H. influenzae 0 0 3 43 0
M. catarrhalis 0 8 3 0 19
Table 2. Confusion matrix (KNN, when k=1) of the bacterial samples without P. aeruginosa. The
interpretations were made in the same manner as in Table 1.
Estimate
S. aureus S. pneumoniae H. influenzae M. catarrhalis
True
S. aureus 49 0 0 0
S. pneumoniae 2 43 5 2
H. influenzae 0 3 43 0
M. catarrhalis 0 3 0 27




